Company Analysis Dyne Therapeutics, Inc.
1. Summary
Advantages
- Price (13.15 $) is less than fair price (31.58 $)
Disadvantages
- Dividends (0%) are below the sector average (0.5248%).
- The stock's return over the last year (-70.95%) is lower than the sector average (-12.88%).
- Current debt level 3.47% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-88.03%) is lower than the sector average (ROE=105.9%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
Dyne Therapeutics, Inc. | Healthcare | Index | |
---|---|---|---|
7 days | 0.2% | -15.6% | 1.6% |
90 days | 37.4% | -8.8% | 12.2% |
1 year | -70.9% | -12.9% | 26.8% |
DYN vs Sector: Dyne Therapeutics, Inc. has significantly underperformed the "Healthcare" sector by -58.06% over the past year.
DYN vs Market: Dyne Therapeutics, Inc. has significantly underperformed the market by -97.71% over the past year.
Stable price: DYN is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: DYN with weekly volatility of -1.36% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (13.15 $) is lower than the fair price (31.58 $).
Price significantly below the fair price: The current price (13.15 $) is 140.2% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (-3.63) is higher than that of the sector as a whole (-267.07).
P/E vs Market: The company's P/E (-3.63) is higher than that of the market as a whole (-118.38).
4.3. P/BV
P/BV vs Sector: The company's P/BV (3.52) is lower than that of the sector as a whole (257.8).
P/BV vs Market: The company's P/BV (3.52) is lower than that of the market as a whole (40.71).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (56.36).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (137.25).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-5.73) is lower than that of the sector as a whole (11.97).
EV/Ebitda vs Market: The company's EV/Ebitda (-5.73) is higher than that of the market as a whole (-93.2).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 87.6% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (87.6%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-22.85%).
5.4. ROE
ROE vs Sector: The company's ROE (-88.03%) is lower than that of the sector as a whole (105.9%).
ROE vs Market: The company's ROE (-88.03%) is lower than that of the market as a whole (-22.57%).
5.5. ROA
ROA vs Sector: The company's ROA (-74.14%) is lower than that of the sector as a whole (-2.97%).
ROA vs Market: The company's ROA (-74.14%) is lower than that of the market as a whole (39.67%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-36.69%) is lower than that of the sector as a whole (0.8343%).
ROIC vs Market: The company's ROIC (-36.69%) is lower than that of the market as a whole (8.74%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5248%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription